Fig. 8.

Exosomal miR-1238 conferred TMZ resistance to GBM cells in vivo. A: Representative pseudocolour bioluminescence images of orthotopic tumours derived from N3 s cells fed with resistant exosomes or 1238-down exosomes after treatment with vehicle or TMZ on the days indicated (n = 10 per group). B: Bioluminescence was quantified in tumours from four groups. C: Representative H&E staining for tumour cytostructures. Scale bars = 100 mm (left panels) and 100 mm (bottom panels). D: Survival curves of mice harbouring intracranial xenografts. E: TUNEL staining of N3 s cells injected into mice treated with TMZ plus exosomal treatment (scale bars = 200 μm). F: Relative expression of miR-1238 in serum samples was measured by RT-qPCR. In all experiments, bars represent mean ± SD from three replicates. (Statistical analysis was performed by Student‘s t-test, *P < .05, **P < .01.)